The Revolution will be RAS(ON) in pancreatic cancer

Revolution Medicine’s Phase III data show that pan-RAS(ON) inhibition can drive meaningful efficacy in pancreatic ductal adenocarcinoma without setting off major safety signals. If approved, daraxonrasib would represent a leap forward for one of the hardest-to-treat cancers, while setting a high bar for the growing wave of RAS-targeting therapies advancing through the clinic.

Revolution Medicines Inc. (NASDAQ:RVMD) had one of the most anticipated readouts at this year’s American Society of Clinical Oncology meeting. In the Phase III RASolute 302 trial, oral daraxonrasib significantly improved survival versus chemotherapy in previously treated patients with pancreatic ductal adenocarcinoma (PDAC)...